Logo Logo
Hilfe
Hilfe
Switch Language to English

Held, Friederike ORCID logoORCID: https://orcid.org/0009-0008-1190-9435; Uibel, Paula; Berberich, Cornelius; Schaller-Nagengast, Jonas; Mitrevski, Vasil; Hutter, Leo; Tumani, Hayrettin ORCID logoORCID: https://orcid.org/0000-0002-1647-6201; Havla, Joachim ORCID logoORCID: https://orcid.org/0000-0002-4386-1340; Gasperi, Christiane ORCID logoORCID: https://orcid.org/0000-0002-0524-6005; Mühlau, Mark ORCID logoORCID: https://orcid.org/0000-0002-9545-2709; Berthele, Achim ORCID logoORCID: https://orcid.org/0000-0001-9650-6222; Kirschke, Jan S. ORCID logoORCID: https://orcid.org/0000-0002-7557-0003 und Hemmer, Bernhard ORCID logoORCID: https://orcid.org/0000-0001-5985-6784 (2025): Replication of the 2023 radiologically isolated syndrome criteria in a multi-centre cohort. In: Brain Communications, Bd. 7, Nr. 5, fcaf323 [PDF, 858kB]

[thumbnail of fcaf323.pdf]
Vorschau
Creative Commons: Namensnennung 4.0 (CC-BY)
Veröffentlichte Version

Abstract

Radiologically isolated syndrome (RIS) represents a pivotal stage for identifying individuals at high risk of transitioning into multiple sclerosis (MS). Early therapy initiation reduces the risk of conversion. The 2023-RIS criteria were proposed to identify presymptomatic individuals earlier. We aimed to replicate the diagnostic value of the 2023-RIS criteria in an independent cohort. In this retrospective cohort study, individuals diagnosed with RIS and longitudinally followed in three centres were stratified by the 2009- and 2023-RIS criteria. We conducted comparative analyses, including survival, hazard ratio and performance evaluations. Among n = 136 individuals, 27.2% converted to MS between 2009 and 2024 (observation time 55.4 months). We confirmed improved identification of individuals at risk using the 2023-RIS criteria (HR 4.30, P < 0.05; HR 4.71, P < 0.05) compared to 2009-RIS criteria (HR 1.32, P = 0.4; HR 1.43; P = 0.3) in 5- and 10-year intervals, respectively. 2023-RIS criteria demonstrated high sensitivity (94%) and negative predictive value (94%) but low specificity (29%). Adding CSF immunoglobulin G and M indices as an additional parameter following RIS diagnosis enhanced risk prediction specificity. We confirm the high sensitivity and predictive value of the 2023-RIS criteria for identifying individuals at risk of conversion to MS and suggest adding immunoglobulin indices to further improve specificity.

Dokument bearbeiten Dokument bearbeiten